Table 2. TILs as a prognostic biomarker in eTNBC.
| Author, year, reference | N | Outcomes | Results |
|---|---|---|---|
| Agarwal et al., 2023, (62) | 108 | DFS and OS | High sTIL associated with better DFS and OS |
| de Jong et al., 2022, (64) | 441 | OS and DRFS | Each 10% sTIL decrease risk of death in 19% (hazard ratio: 0.81) |
| De Jong et al., 2020, (78) | 481 | OS and DRFS | Each 10% sTIL decrease risk of event in 17% (hazard ratio: 0.83) |
| Loi et al., 2022, (79) | 2,148 | IDFS, DDFS, and OS | Each 10% sTIL decrease risk of event in 13–17% (IDFS, hazard ratio: 0.87; DDFS, hazard ratio: 0.83; OS, hazard ratio: 0.84) |
| Gluz et al., 2022, (67) | 336 | IDFS, DDFS, and OS | High sTIL associated with better IDFS, DDFS, and OS |
| Gao et al., 2020, (59) | 18,170 | DFS and OS | High sTIL associated with increased DFS (hazard ratio: 0.907) and OS (hazard ratio: 0.869) |
| Park et al., 2019, (80) | 476 | IDFS, DDFS, and OS | High sTIL stage I: 5-year IDFS 91%; 5-year DDFS 97%; 5-year OS 98% |
| Denkert et al., 2018, (55) | 906 | DFS and OS | Each 10% sTIL decrease risk of event in 7–8% (DFS, hazard ratio: 0.93; OS, hazard ratio: 0.92) |
| Leon-Ferre et al., 2018, (81) | 605 | IDFS and OS | Lower TIL associated with worse IDFS and OS |
| Pruneri et al., 2016, (71) | 897 | DFS, DDFS, and OS | Each 10% TIL better DFS, DDFS, and OS |
| Pruneri et al., 2016, (57) | 647 | BCFI, DFS, DRFI, and OS | Each 10% TILs decrease risk of event 11–17% (BCFI, hazard ratio: 0.87; DFS, hazard ratio: 0.89; DRFI, hazard ratio: 0.84; OS, hazard ratio: 0.83) |
| Tian et al., 2016, (58) | 425 | DFS, DDFS, and OS | Each 10% sTILs decrease risk of event 5% (recurrence or death) |
| Dieci et al., 2015, (82) | 199 | OS | OS 10-year: HT 89%, LT 68% |
| Adams et al., 2014, (56) | 481 | DFS, OS, and DRFI | Each 10% sTIL decrease risk of event in 14% |
| Dieci et al., 2014, (77) | 278 | MFS and OS | Each 10% sTIL decrease risk of event in 21% (mets or death) |
| Loi et al., 2013, (83) | 256 | DFS and OS | Each 10% sTIL decrease risk of event 15–17% |
TILs, tumor-infiltrating lymphocytes; eTNBC, early-stage TNBC; TNBC, triple-negative breast cancer; DFS, disease-free survival; OS, overall survival; sTIL, stromal TIL; DRFS, distant relapse-free survival; IDFS, invasive DFS; DDFS, distant DFS; BCFI, breast cancer-free interval; DRFI, distant recurrence-free interval; HT, high TILs; LT, low TILs; MFS, metastasis-free survival.